These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29416369)

  • 1. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis.
    Uemura N; Kinoshita Y; Haruma K; Yao T; Kushima R; Kanoo T
    Clin Exp Gastroenterol; 2018; 11():51-56. PubMed ID: 29416369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
    Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
    BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
    Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
    Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.
    Iwakiri K; Sakurai Y; Shiino M; Okamoto H; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Ashida K
    Therap Adv Gastroenterol; 2017 Jun; 10(6):439-451. PubMed ID: 28567114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
    Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
    Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
    Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
    Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
    Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
    Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
    Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
    Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review with meta-analysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis.
    Simadibrata DM; Lesmana E; Pratama MIA; Sugiharta AJ; Winarizal AS; Lee YY; Syam AF
    JGH Open; 2024 Mar; 8(3):e13053. PubMed ID: 38523708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors.
    Mizuno H; Yamada K; Minouchi K; Kamiyamamoto S; Hinoue Y
    Biomed Rep; 2018 Feb; 8(2):148-155. PubMed ID: 29435273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
    Yang S; Deng W; Xie Z; Chen J
    Medicine (Baltimore); 2022 Nov; 101(47):e31807. PubMed ID: 36451489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
    Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
    Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of vonoprazan in patients with erosive esophagitis.
    Zhang M; Xiao Y; Chen M
    Therap Adv Gastroenterol; 2022; 15():17562848221122623. PubMed ID: 36117573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.
    Savarino E; Martinucci I; Furnari M; Romana C; Pellegatta G; Moscatelli A; Bodini G; Marabotto E; Savarino V; de Bortoli N; Blandizzi C
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1333-1341. PubMed ID: 27428571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
    Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
    Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial.
    Kawai D; Takenaka R; Ishiguro M; Okanoue S; Gotoda T; Kono Y; Takemoto K; Tsugeno H; Fujiki S
    BMC Gastroenterol; 2021 May; 21(1):236. PubMed ID: 34022796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.